Premium
Potential role for statins in sickle cell disease
Author(s) -
Adam Soheir S.,
Hoppe Carolyn
Publication year - 2013
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.24443
Subject(s) - medicine , inflammation , nitric oxide , disease , pathophysiology , cell adhesion molecule , statin , pharmacology , bioinformatics , immunology , biology
The complex pathophysiology of sickle cell disease (SCD) is remarkably similar to that observed in other chronic vascular diseases and involves multiple biologic pathways triggered by ischemia reperfusion injury, coagulation activation, and inflammation. Statins are potent lipid‐lowering agents commonly used to reduce the risk of cardiovascular disease. Independent of their lipid lowering effect, statins have been shown to down‐regulate inflammatory mediators and endothelial adhesion molecules, reduce tissue factor expression and restore nitric oxide bioavailability. The pleiotropic effects of statins make these agents attractive therapeutic candidates for SCD. This article reviews available evidence for the potential role of statins in SCD. Pediatr Blood Cancer 2013; 60: 550–557. © 2012 Wiley Periodicals, Inc.